NCT06888622

BLAZE-Limiting Approach in NMOSD

Eculizumab for Blaze-limiting Approach in NMOSD: A Prospective Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 9 (actual)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651). Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.

Conditions

• Neuromyelitis Optica Spectrum Disorders (NMOSD)

Interventions

Type	Name	Description
DRUG	Eculizumab administration	Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks

Timeline

• Start date: 2023-10-01
• Primary completion: 2025-03-01
• Completion: 2025-03-03
• First posted: 2025-03-21
• Last updated: 2025-03-21

Locations

1 site across 1 country: China